Burning Rock Biotech Limited
Burning Rock Biotech Limited
Your view on BNR
Overview
What the company does, where it operates, and who runs it.
About Burning Rock Biotech Limited
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Yusheng Han
- Headquarters
- No. 5, Xingdao Ring Road North, Guangzhou, CN
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Yusheng Han
- Headquarters
- No. 5, Xingdao Ring Road North, Guangzhou, CN
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.
The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.
Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency.
In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China.
It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Burning Rock Biotech Limited, and the rating behind it. BNR last traded at $12.08; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Burning Rock Biotech Limited. Starting points for Burning Rock Biotech Limited: EPS -$56.39, beta 1.39 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Burning Rock Biotech Limited. Burning Rock Biotech Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Burning Rock Biotech Limited. Trailing twelve-month EPS for Burning Rock Biotech Limited stands at -$56.39. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Burning Rock Biotech Limited. Burning Rock Biotech Limited has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Burning Rock Biotech Limited valued side by side against its closest peers. Burning Rock Biotech Limited is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Burning Rock Biotech Limited, and how their positions are changing. At a $12.8M market value, institutional positions materially move Burning Rock Biotech Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Burning Rock Biotech Limited executives and directors. Shares of Burning Rock Biotech Limited have traded between $2.18 and $16.28 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Burning Rock Biotech Limited. Burning Rock Biotech Limited is a $12.8M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Burning Rock Biotech Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Burning Rock Biotech Limited. Coverage tracks Burning Rock Biotech Limited within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.